[ET Net News Agency, 3 June 2021] Goldman Sachs raised its target price for Innovent
Biologics (01801) to HK$100.3 from HK$93.5 and maintained its "buy" rating.
The research house said key risks include (1) intensifying competition in the PD-1/L1
market in China; (2) uncertain approval timeline for key candidates; (3) potential
restrictions on off-label use arising from any safety issues; and (4) failure of R&D
projects. (RC)